BRCC3 and hepatocellular carcinoma: Furthermore, TFPI2 overexpression under sorafenib treatment significantly upregulated BRCC3, CCAR2, and GADD45A protein levels (Figure S8G), suggesting that TFPI2 enhanced the sensitivity of HCC to sorafenib through the BRCC3/CCAR2/GADD45A axis.